Amgen (AMGN 0.20%) reported its first-quarter results on April 27, 2021. Those results weren't very impressive. In this Motley Fool Live video, recorded on April 28, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not investors should worry after the biotech's Q1 update.
Keith Speights: Let's switch gears and talk about some earnings. One of the biggest biotechs in the world, Amgen, reported its first-quarter earnings on Tuesday. Brian, I know you've taken a look at Amgen's results. Were there anything for investors to worry about with the company's update?
Brian Orelli: Yeah. The company is really dealing with two main issues. One is that people aren't necessarily still going to their doctor for things that aren't life-threatening, and so then that's causing slightly lower volumes for those drugs.
But it's also having to discount a lot of its drugs. For instance, its migraine treatment, Aimovig, grew 20 percent in volume, but recorded 7 percent lower revenue because had discounted the drug so much.
It's sticking with 2021 revenue and adjusted earnings guidance. So the company thinks it will pick up in the second half as more people will get vaccinated and feel more comfortable going back to their doctor.
They upped the high end of the guidance for share repurchases, so they could buy back as much as $5 billion in stock this year. So I think they're trying to prop up their earnings per share by reducing the number of shares in the denominator.
Speights: I was looking at Amgen's earnings yesterday, and I noticed of the company's top five best-selling drugs, four of them saw sales declines, year-over-year sales declines. I guess the worst too was the company's No. 1 and No. 2 drugs. Enbrel saw sales drop 20 percent year over year, Neulasta saw sales drop 21 percent year over year as it faces biosimilar competition.
There was one, I guess, asterisk in there. Otezla, which is an autoimmune disease drug that Amgen bought to help grease the wheels for the Bristol Myers Squibb acquisition of Celgene last year. Otezla saw sales drop about 1 percent, but that was mainly because of rebates.
That's probably just a temporary deal, and I suspect we'll see Otezla return to solid growth going forward. But still four out of five drugs experiencing sales declines out of the top five, not a good story, right?
Orelli: Yeah, No. That's never a good thing when your top-selling drugs have stopped growing or even started to decline. That makes it hard even when you add new drugs because they're going to be so much smaller when they begin that when you add these new drugs and ramp up sales there, you can sometimes not even be able to make up for the loss of the large selling drugs.
Speights: You mentioned Amgen doing share buybacks. The company had, I think, around $10.6 billion or so in cash and equivalents at the end of the first quarter.
Amgen has already announced a couple of acquisitions this year. It completed the acquisition of Five Prime Therapeutics, it also announced that it's buying a small biotech, Rodeo Therapeutics. Brian, my guess, my prediction, anyway, is that we're going to see Amgen use a good bit more of its cash to make more deals. What do you think?
Orelli: Yeah, I think that even if they used all 5 billion, they're going to have some cash float in there, too, so I think that still leaves them plenty of cash to add to the pipeline.
